MicroArray - Ovarian cancer management using microarrays
From 01-01-2003 to 31-12-2006
Description
We will use microarrays to measure expression levels of a given set of genes in ovarian tumor cells (ovarian tumors taken from the tissue collections – see above). This gives, for each experiment, an expression vector with thousands of components (1 component for each probe or gene present on the array). The determination of these expression levels can be repeated for ovarian tumor cells coming from different classes. For example:- Tumors with a different histological diagnosis (e.g., serous versus mucinous, well differentiated versus poorly differentiated)
- Tumors in a different stage of development (e.g., stage I or more)
- Tumors with a different effect of therapy (e.g, with and without platinum resistance)
- Tumors with a different prognosis (e.g., disease-free survival versus relapse in for stage I tumors or stage I tumors with and without subclinical metastases; indolent versus more aggressive disease)
- Benign, malignant and borderline ovarian tumors/tissues
- Primary tumor versus metastasis (taken during primary surgery)
- Tumor taken before and after chemotherapy
Team
- Bart De Moor, Co-promoter
- Vergote, Promoter (External)
- Olivier Gevaert, Team member
Financing
Funding: FWO - Research Foundation - Flanders
Program/Grant Type: FWO Research Grant - FWO Research Grant
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.